Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
2023; Massachusetts Medical Society; Volume: 388; Issue: 22 Linguagem: Inglês
10.1056/nejmoa2214131
ISSN1533-4406
AutoresNicholas C. Turner, Mafalda Oliveira, Sacha J. Howell, Florence Dalenc, Javier Cortés, Henry Gómez, Xichun Hu, Komal Jhaveri, Petr Krivorotko, Sibylle Loibl, Serafín Morales, Meena Okera, Yeon Hee Park, Joohyuk Sohn, Masakazu Toi, Eriko Tokunaga, Samih Yousef, Lyudmila Zhukova, Elza C. de Bruin, Lynda Grinsted, Gaia Schiavon, Andrew Foxley, Hope S. Rugo,
Tópico(s)Cancer-related Molecular Pathways
ResumoAKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy, in patients with hormone receptor-positive advanced breast cancer are limited.
Referência(s)